Video | Agriculture | Confidence | Economy | Energy | Employment | Finance | Media | Property | RBNZ | Science | SOEs | Tax | Technology | Telecoms | Tourism | Transport | Search

 

Maxigesic to carry Gold Cross logo

Media release

18 March 2016

Maxigesic to carry Gold Cross logo of the Pharmacy Guild of Australia

Australia and New Zealand pharmaceutical company, AFT Pharmaceuticals, has today announced that specific 24 tablet packets of its Maxigesic analgesic will soon carry the Pharmacy Guild of Australia’s ‘Gold Cross’ logo.

Founder and Managing Director of AFT Pharmaceuticals, Dr Hartley Atkinson, says he is delighted with the partnership with the Guild.

“For decades, Australians have associated the Gold Cross with trusted advice and support from community pharmacies. For the Guild to extend the logo to Maxigesic is fantastic because it’s an instantly recognisable mark of quality,” said Dr Atkinson.

Maxigesic provides double-action relief from a wide range of pain using a patented combination of Paracetamol and Ibuprofen. An important point of difference is that the product is free of any codeine.

Dr Atkinson says that being codeine-free has undoubtedly been a factor in the success of Maxigesic in Australia in light of concerns expressed by a number of medical professionals about the risks of dependence from codeine-based painkillers.

Trevor Clarkin, General Manager, Gold Cross Products & Services Pty Ltd, a fully owned subsidiary of The Pharmacy Guild of Australia, outlined that the company was pleased to have entered into an endorsement agreement for Maxigesic with AFT Pharmaceuticals.

“The endorsement is testament to the quality and value the product has built in Australian community retail pharmacy. We congratulate Hartley Atkinson and his team and look forward to a long and rewarding partnership together,” Mr Clarkin added.

Dr Atkinson says that the partnership further illustrated the company’s desire to deliver on what was signalled in the Product Disclosure Statement as part of AFT’s float on the NZX and ASX Main Board last year.

“Australia is our biggest market for Maxigesic and we expect this partnership to help deliver a significant boost in its sales. Additional revenues from the deal will largely be reinvested in raising Maxigesic brand awareness across Australia. We’ve also just ticked over licensing and distribution deals for Maxigesic in 98 different countries. So today’s announcement is just another example of AFT getting the runs on the board really.”

Dr Atkinson says he anticipates Maxigesic packs carrying the Gold Cross logo to start appearing in Australian pharmacies from June.

[End of release]


© Scoop Media

 
 
 
Business Headlines | Sci-Tech Headlines

 

Ground Rules: Government Moves To Protect Best Growing Land

“Continuing to grow food in the volumes and quality we have come to expect depends on the availability of land and the quality of the soil. Once productive land is built on, we can’t use it for food production, which is why we need to act now.” More>>

ALSO:

Royal Society: Calls For Overhaul Of Gene-Technology Regulations

An expert panel considering the implications of new technologies that allow much more controlled and precise ‘editing’ of genes, has concluded it’s time for an overhaul of the regulations and that there’s an urgent need for wide discussion and debate about gene editing... More>>

ALSO:

Retail: Card Spending Dips In July

Seasonally-adjusted electronic card spending dipped in July by 0.1 percent after being flat in June, according to Stats NZ. Economists had expected a 0.5 percent lift, according to the median in a Bloomberg poll. More>>

ALSO:

Product Stewardship: Govt Takes More Action To Reduce Waste

The Government is proposing a new way to deal with environmentally harmful products before they become waste, including plastic packing and bottles, as part of a wider plan to reduce the amount of rubbish ending up in landfills. More>>

ALSO:

Earnings Update: Fonterra Sees Up To $675m Loss On Writedowns

“While the Co-op’s FY19 underlying earnings range is within the current guidance of 10-15 cents per share, when you take into consideration these likely write-downs, we expect to make a reported loss of $590-675 million this year, which is a 37 to 42 cent loss per share." More>>

ALSO: